1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Eli Lilly and Company - Product Pipeline Review - 2016

Eli Lilly and Company - Product Pipeline Review - 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 242 pages

Eli Lilly and Company - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Eli Lilly and Company - Product Pipeline Review - 2016’, provides an overview of the Eli Lilly and Company’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Eli Lilly and Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Eli Lilly and Company
- The report provides overview of Eli Lilly and Company including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Eli Lilly and Company’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Eli Lilly and Company’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Eli Lilly and Company’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Eli Lilly and Company
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Eli Lilly and Company’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

Eli Lilly and Company - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Eli Lilly and Company Snapshot 7
Eli Lilly and Company Overview 7
Key Information 7
Key Facts 7
Eli Lilly and Company - Research and Development Overview 8
Key Therapeutic Areas 8
Eli Lilly and Company - Pipeline Review 17
Pipeline Products by Stage of Development 17
Pipeline Products - Monotherapy 18
Pipeline Products - Combination Treatment Modalities 19
Pipeline Products - Partnered Products 20
Pipeline Products - Out-Licensed Products 22
Eli Lilly and Company - Pipeline Products Glance 24
Eli Lilly and Company - Late Stage Pipeline Products 24
Eli Lilly and Company - Clinical Stage Pipeline Products 27
Eli Lilly and Company - Early Stage Pipeline Products 31
Eli Lilly and Company - Drug Profiles 33
baricitinib 33
duloxetine hydrochloride DR 36
ixekizumab 38
necitumumab 39
olaratumab 42
ramucirumab 44
cetuximab 50
abemaciclib 57
AMG-5041 59
insulin peglispro 60
LY-2951742 62
odelepran hydrochloride 64
solanezumab 65
tadalafil 67
galunisertib 69
blosozumab 71
edivoxetine hydrochloride 72
emibetuzumab 74
erteberel 75
icrucumab 76
insulin lispro U100 77
landogrozumab 79
LY-2510924 80
LY-2623091 82
LY-2874455 83
LY-2928057 84
LY-2944876 85
LY-3015014 87
LY-3016859 88
LY-3023414 89
LY-3074828 91
merestinib 92
prexasertib 93
ralimetinib mesylate 95
LY-2780301 96
LY-3039478 97
Biologic 6 for Diabetes 98
Biologic for Crohn's Disease 99
Biologic for Diabetic Nephropathy 100
Biologic for Hypoglycemia 101
Biologic for Lupus 102
Biologic for Neutrophilic Dermatosis 103
Biologic for Renal Anemia 104
dulaglutide 105
insulin lispro U200 108
LY-2599666 109
LY-2969822 110
LY-3002813 111
LY-3009120 112
LY-3022855 113
LY-3025876 114
LY-3041658 115
LY-3050258 116
LY-3076226 117
LY-3079514 118
LY-3090106 119
LY-3108743 120
LY-3114062 121
LY-3127760 122
LY-3127804 123
LY-3143753 124
LY-3154207 125
LY-3164530 126
LY-3185643 127
LY-3200327 128
LY-3202626 129
LY-3337641 130
LY-900014 131
Recombinant Protein for Parkinson's Disease 132
Small Molecule 4 for Diabetes 133
cercosporamide 134
CPZEN-45 136
LLY-2707 137
LSN-2463359 138
LSN-2535717 139
LSN-2814617 140
LY-2109761 141
LY-2607540 142
LY-2811376 + LY-3002813 143
LY-2857785 144
LY-344545 145
Monoclonal Antibody Conjugate 2 for Oncology 146
Monoclonal Antibody Conjugate 3 for Oncology 147
Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology 148
ND-09759 149
Small Molecule to Agonize TR-Beta for Dyslipidemia 150
Small Molecule to Antagonize mGlu5 for Pain 151
Drugs for Oncology 152
IC-87201 153
Monoclonal Antibodies for Undisclosed Indication 154
Small Molecule for Type 2 Diabetes 155
Small Molecule to Antagonize EP4 Receptor for Pain and Inflammation 156
Small Molecule to Inhibit MPGES-1 for Inflammation and Pain 157
Eli Lilly and Company - Pipeline Analysis 158
Eli Lilly and Company - Pipeline Products by Target 158
Eli Lilly and Company - Pipeline Products by Route of Administration 165
Eli Lilly and Company - Pipeline Products by Molecule Type 166
Eli Lilly and Company - Pipeline Products by Mechanism of Action 167
Eli Lilly and Company - Recent Pipeline Updates 171
Eli Lilly and Company - Dormant Projects 203
Eli Lilly and Company - Discontinued Pipeline Products 207
Discontinued Pipeline Product Profiles 209
Eli Lilly and Company - Company Statement 220
Eli Lilly and Company - Locations and Subsidiaries 224
Head Office 224
Other Locations and Subsidiaries 224
Eli Lilly and Company - Key Manufacturing Facilities 232
Appendix 233
Methodology 233
Coverage 233
Secondary Research 233
Primary Research 233
Expert Panel Validation 233
Contact Us 233
Disclaimer 234

List of Tables
Eli Lilly and Company, Key Information 15
Eli Lilly and Company, Key Facts 15
Eli Lilly and Company - Pipeline by Indication, 2016 17
Eli Lilly and Company - Pipeline by Stage of Development, 2016 25
Eli Lilly and Company - Monotherapy Products in Pipeline, 2016 26
Eli Lilly and Company - Combination Treatment Modalities in Pipeline, 2016 27
Eli Lilly and Company - Partnered Products in Pipeline, 2016 28
Eli Lilly and Company - Partnered Products/ Combination Treatment Modalities, 2016 29
Eli Lilly and Company - Out-Licensed Products in Pipeline, 2016 30
Eli Lilly and Company - Out-Licensed Products/ Combination Treatment Modalities, 2016 31
Eli Lilly and Company - Pre-Registration, 2016 32
Eli Lilly and Company - Filing rejected/Withdrawn, 2016 33
Eli Lilly and Company - Phase III, 2016 34
Eli Lilly and Company - Phase II, 2016 35
Eli Lilly and Company - Phase I, 2016 37
Eli Lilly and Company - Preclinical, 2016 39
Eli Lilly and Company - Discovery, 2016 40
Eli Lilly and Company - Pipeline by Target, 2016 166
Eli Lilly and Company - Pipeline by Route of Administration, 2016 173
Eli Lilly and Company - Pipeline by Molecule Type, 2016 174
Eli Lilly and Company - Pipeline Products by Mechanism of Action, 2016 175
Eli Lilly and Company - Recent Pipeline Updates, 2016 179
Eli Lilly and Company - Dormant Developmental Projects,2016 211
Eli Lilly and Company - Discontinued Pipeline Products, 2016 215
Eli Lilly and Company, Subsidiaries 232
Eli Lilly and Company, Key Manufacturing Facilities 240

List of Figures
Eli Lilly and Company - Pipeline by Top 10 Indication, 2016 17
Eli Lilly and Company - Pipeline by Stage of Development, 2016 25
Eli Lilly and Company - Monotherapy Products in Pipeline, 2016 26
Eli Lilly and Company - Partnered Products in Pipeline, 2016 28
Eli Lilly and Company - Out-Licensed Products in Pipeline, 2016 30
Eli Lilly and Company - Pipeline by Top 10 Target, 2016 166
Eli Lilly and Company - Pipeline by Route of Administration, 2016 173
Eli Lilly and Company - Pipeline by Molecule Type, 2016 174
Eli Lilly and Company - Pipeline Products by Top 10 Mechanism of Action, 2016 175

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ...

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H2 2016

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H2 2016 ...

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2016

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Transmembrane Prolyl 4 Hydroxylase ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.